Biopharma needs to address its workforce training methods By Karen Langhauser, Chief Content Director Nov 14, 2019 The world can’t stop talking about biopharma’s scientific achievements, but the discussion often avoids the industry’s biggest potential buzzkill: a shortage of properly trained workers to manufacture these new drugs. There’s no denying that biopharma drugs will play a vital role in the future of medicine. Biologics make up about 40 percent of the over 16,000 drugs in the global pharma pipeline. These biologic hopefuls include drugs in new therapeutic areas, such as cell and gene therapy, that are igniting the industry on fire with their potential to treat the previously untreatable. The U.S. Food and Drug Administration estimated that by 2020, they will be receiving more than 200 Investigational New Drug applications for gene and cell therapies per year, and have subsequently hired more clinical reviewers to avoid approval bottlenecks. Click Here For Complete Article Text
|
|||||||||||||||||||||||||||
| Application Sequencing | |||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||
| Company | Product | Process | Other Subjects | Event | Event Date | Location | Publication | Publication Date | Text Descriptor | ||||||||||||||||||
|
|
|
|
|
|
|
|
||||||||||||||||||||